SCOTTSDALE, Ariz., Jun. 11, 2015 /PRNewswire/ --RiceBran Technologies (NASDAQ: RIBT and RIBTW), a global leader in the production and marketing of value added products derived from rice bran, today announced that the results of a study performed by a team of researchers from the University of Leicester, Loughborough University, Leicester, UK, and Glenfield Hospital, Leicester, UK were accepted for publication on May 29, 2015 in Molecular Nutrition & Food Research. The online pre-publication is titled “Search for novel circulating cancer chemopreventive biomarkers of dietary rice bran intervention in ApcMin mice model of colorectal carcinogenesis, using proteomic and metabolic profiling strategies” and will appear in its final edited version in a future edition of the scientific journal.
Dr. Robert Smith, SVP Operations and R&D for RiceBran Technologies commented: “The health benefits of our RiFiber and other processs-patented ingredients are well documented, as can be seen in the Claims Substantiation Study completed in February 2015 which is available on our website. This latest study by University of Leicester researchers provides further insights into potential mechanisms for reducing the development of intestinal adenomas through consumption of rice bran and rice bran derivatives that are sources of dietary fiber. Our process patented RiFiber was used in this study and the results indicate its potential as a chemopreventive ingredient that supports gastrointestinal health.”
W. John Short, CEO & President of RiceBran Technologies noted: “As baby boomers move from pharmacy to grocery that is, away from pills and medications to healthy, whole food nutrition - our proprietary and process-patented products have a significant role to play with major consumer product companies and specialty functional food manufacturers. The health benefits of our products go well beyond the fundamental benefits demanded by consumers - non-genetically modified, gluten free, soy free, minimally processed to identifiable health benefits backed by our own and third party clinical trials in both human and animal systems. This most recent study conducted at the University of Leicester, reinforces what we know about the health benefits of our proprietary and process-patented RiBran, RiSolubles and RiFiber products. We are very well positioned to partner with cutting edge functional food and ingredient companies to develop new sources of healthy, whole food nutrition that can have positive impacts on consumer health.”
Working with RiceBran Technologies RiFiber rice bran derivative, which is high in insoluble dietary fiber, the UK study demonstrates a dose-dependent reduction in intestinal adenomas in ApcMin mice that consumed a diet containing RiFiber. ApcMin mice possess a heritable Apc gene mutation which is responsible for adenoma mutation and serve as a model for colorectal carcinogenesis.
The UK scientists showed that consumption of RiFiber in ApcMin mice was associated with changes in metabolic pathways as evidenced by metabolic profiling. Moreover, proteomic analysis identified adiponectin as a component that was significantly elevated in the RiFiber fed mice. Elevated levels of adiponectin have previously been associated with a suppression of carcinogenesis in ApcMin mice, and with skeletal muscle mass increase and fat cell reduction in human studies.
The full text of the 2015 RiFiber study can be found at:
http://onlinelibrary.wiley.com/doi/10.1002/mnfr.201400818/abstract
For information on RiceBran Technologies proprietary and process-patented functional food and human ingredients, please contact Mark McKnight, SVP of Sales and Marketing at mmcknight@ricebrantech.com or Joon Park, Vice President of Human Ingredient Sales at jpark@ricebrantech.com .
About RiceBran Technologies
RiceBran Technologies is a packaged functional food, human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from stabilized rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows us to convert raw rice bran, one of the world’s most underutilized food sources, into a number of highly nutritious functional foods, human food ingredients and animal nutrition products. Our target markets are functional food, nutricosmetic, human food ingredient and animal nutrition manufacturers and retailers, as well as natural food, functional food, nutricosmetic and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in our filings with the SEC and by visiting our website at www.ricebrantech.com .
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements about study results related to the health benefits of RiceBran Technologies’ proprietary and process-patented ingredients. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties. RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-lookin information can be found in RiceBran Technologies’ filings with the Securities and Exchange Commission, including its most recent periodic reports.
Investor Contact:
Ascendant Partners, LLC
Fred Sommer
+1-(732)410-9810
fred@ascendantpartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ricebran-technologies-patented-rifiber-shows-dose-dependent-reduction-in-benign-tumor-cells-in-genetic-mouse-model-300097653.html
SOURCE RiceBran Technologies
Help employers find you! Check out all the jobs and post your resume.
